info@emcapital.com.hk
(852) 2960 2388
Close

Explore Our Insights

HomeExplore Our Insights

Why Biotechnology and Healthcare Industry

Biotechnology and healthcare industry has been a blooming industry for the past few years. With increasing concerns about healthcare and quality of well-beings, through discovery of new molecules, biotech innovations are able to address our urgent needs: fighting diseases; generating clean energy.
Market Size in 2015: USD 330.3 billion
0
Potential Market Size: >USD 775.2 billion
0
CAGR 2016-2024: 9.9%
0

(Source: Global Market Insights)

Experience the Difference

Great Potential

Great Potential

The continuous ageing population, together with growing population of the middle class creates a surge of concern on well-beings of citizens. Healthcare industry has become the top priority in China where the value of such industry is forecast to be RMB 8 trillion by 2020, as proposed in China’s 13th Five-Year Plan (FYP). (Source: KPMG Global China Practice)

Learn more
Strong State Support

Strong State Support

Biotechnology industry has been the main target since Chinese government’s previous plan, 12th FYP, where 1.7 trillion was injected into this industry. With the goal of doubling the industry’s scale through scaling up of a new generation of biotechnology products and services in its recent 13th FYP, China’s pharma innovation continues to spur through strong state support

Learn more
Biggest Consumer Market

Biggest Consumer Market

The current population in China is approximately 1.42 billion which holds around one third of world population. This opens up great opportunities for the development of biotech and healthcare sector.

Learn more
Sustainability

Sustainability

Being the present second largest economy in the world, China has been growing at a sustainable GDP growth rate and is forecast to be the largest economy by 2030s.

Learn more

Industry Leader

0%
Average GDP growth rate since 1989
0%
Expected proportion of aged > 65 in 2030
0%
AAGR of expenditure on R&D (2001-2016)
0%
AAGR of expenditure on Public Health (2001-2016)

Opportunity in Hong Kong

Hong Kong provides favorable conditions and a key to open the door of opportunities for healthcare and biotechnology industry to incubate, foster and bloom. Benefitting from the advantage of “One Country” and protection of “Two Systems”, Hong Kong has long been served as a bridge to connect both worldwide and the Chinese market. With Hong Kong’s stable financial environment, reinforcement of long-established protection by law, and transparency in capital markets, it is the key hub for investment in and out of China. In February 2018, HKEX decided to implement expanding listing regime relaxes listing rules of biopharmaceutical firms, thereby developing the innovation industry in order to enhance sustainability of Hong Kong’s competitiveness. Guangdong-Hong Kong-Macau Bay Area Development underpins HK Government’s support of fostering innovation industry in Hong Kong, which includes the joint development of the HongKong/Shenzhen Innovation and Technology Park at the 87-hectare Loop, as well as an establishment of a health consortium in the Bay Area.

HK Government’s Support on Bio-Innovation Technology Industry

0
HKD 10 billion: Allocation to HKSTPC to reinforce the role of the Science Park as HK’s flagship technology infrastructure
0
HKD 10 billion: Injection into the Innovation and Technology Fund (ITF) to support applied R&D work in HK
0
HKD 20 billion: Fund on first phase of the HK-Shenzhen Innovation and Technology Park in the Lok Ma Chau Loop
0
HKD 10 billion: Earmark to support the establishment of two research clusters on healthcare technologies and on artificial intelligence and robotics technologies
© 2018 Eminent Capital. All Rights Reserved. Powered by Techcomm